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Pulmonary Langerhans’ cell histiocytosis (PLCH) and lymphangioleiomyomatosis (LAM) are two
rare cystic lung diseases of unknown aetiology and different pathogenesis. Although the diag-
nosis can be strongly suspected on the basis of the medical history and clinical and radiological
features, at times a pathological confirmation of the diagnosis is necessary. Surgical lung
biopsy is considered the gold standard in the diagnosis of both LAM and PLCH. However,
bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBB) are less invasive procedures
that can be useful in diagnosis. BAL has a high specificity but low sensitivity for PLCH, and in an
appropriate clinical context it can be used to establish the diagnosis. However, even if a high
percentage of pigment-laden macrophages are found in the BAL fluid of patients with LAM, no
BAL findings are considered suggestive for the disease. TBB shows a low diagnostic yield
(10e40%) in PLCH because of the small amount of tissue obtained and the patchy nature of
the disease, although it may be of more use in LAM.
ª 2010 Elsevier Ltd. All rights reserved.Pulmonary Langerhans’ cell histiocytosis
Pulmonary Langerhans’ cell histiocytosis (PLCH) is an
uncommon interstitial lung disease characterized by the
proliferation of Langerhans’ cell infiltrates. It primarily
affects young adults, and nearly all affected patients have
a history of current or prior cigarette smoking. Lung involve-
ment may occur either in isolation or as part of a multisystem
disorder.1) 2 8599 4580; fax: þ39 (0) 2
.it (S. Harari).
0 Elsevier Ltd. All rights reservedHistologically, the pulmonary lesions begin as a prolifera-
tion of Langerhans’ cells (LCs) along the small airways.2,3 LCs
are differentiated cells of monocyteemacrophage lineage,
distinguished from dendritic cells by their characteristic
cytoplasmic organelles (Birbeck granules) seen on electron
microscopy and their strong expression of the CD1a antigen on
the cell surface.3,4 LCs also stainwith S100 antibody, although
this finding is not specific to these cells and can also be
observed in neuroendocrine cells and some macrophages.4
Pathological findings vary with the stage: in the early
stages numerous LCs invade the terminal and respiratory
bronchioles, destroying the bronchiolar wall in an eccentric
fashion and forming nodules. The nodules include several
inflammatory cells, including LCs, eosinophils, lymphocytes,.
Figure 2 Detail of the cellular infiltrate in nodular lesions of
pulmonary Langerhans’ cell histiocytosis, showing Langerhans’
cells with typical delicate and folded nuclei (haematoxyline
eosin  400).
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progress to cellular and fibrotic nodules, and finally to
fibrotic nodules that can lack LCs entirely (Figs. 1 and 2). In
the end stage, stellate fibrotic scars surrounding cystic
spaces of variable diameter, and paracicatricial emphysema
are the prominent lesions.2
Dyspnoea, cough and pneumothorax are the main clinical
manifestations of PLCH. Other respiratory symptoms include
haemoptysis and chest pain.5 The most common radiological
findings on high-resolution computed tomography (HRCT) are
nodular and irregularly shaped cystic changes, which
predominantly involve the middle and upper lobes, with
sparing of the lung bases (Fig. 3).6 In a young asymptomatic
or low-symptomatic smoker this radiological pattern is so
characteristic that the diagnosis is almost certain and may
obviate the need for invasive investigations.
Bronchoalveolar lavage
In an appropriate clinical context BAL can be used to
establish the diagnosis of PLCH. Differential cell counts may
reveal a moderate increase in the proportion of eosinophils
and neutrophils above that seen in smoking control subjects.
The percentage of lymphocytes is normal or reduced and the
CD4/CD8 ratio is decreased, as in cigarette smokers.7
LCs can be identified in BAL fluid of patients with PLCH
by immunocytochemical techniques using anti-CD1a anti-
bodies. In the early 1980s Chollet and colleagues used
immunofluorescence staining with the monoclonal antibody
OKT6 to detect LCs in BAL fluid. They found that cells
reactive with OKT6 were consistently present in BAL fluid of
patients with PLCH, although with great variability
(1.8e25% of the total number of cells in BAL fluid). Subse-
quent analysis with immunoelectron microscopy showed
that all cells reactive with OKT6 had the characteristics of
LCs. However, small numbers of reactive cells (<3% of total
cells recovered) were found in patients with different
diseases.8 Moreover, an expansion in the population of LCs
on the epithelial surface of the lower respiratory tract, as
detected by monoclonal antibody anti-T6, has been shown
to be associated with cigarette smoking.9Figure 1 Lung biopsy specimen from a patient with pulmo-
nary Langerhans’ cell histiocytosis, showing a nodular lesion
(haematoxylineeosin  100).Comparing patients with histologically proven PLCH with
patients with other lung diseases, including sarcoidosis,
according to their smoking habit, Auerswald found that the
percentage of CD1a-reactive cells in BAL fluid was >5% in all
PLCH cases, and the dividing line of 5% CD1-positive cells was
not influenced by patients’ smoking habits.10 Thus, although
a low-level elevation of CD1a-reactive cells may be difficult
to interpret, when the proportion of CD1a-reactive cells in
the BAL fluid is >5% the diagnosis of PLCH is very likely.
More recently other authors have reported considerably
lower sensitivity (<25%).11 In our experience of 16 patients
with a clinicaleradiological diagnosis of PLCH, we found
CD1a-reactive cells >5% in BAL fluid in four cases (unpub-
lished data). However, in patients with an atypical clinical
and/or radiological presentation BAL can be used to
exclude interstitial lung diseases with more typical lavage
findings (e.g. sarcoidosis) as well as pulmonary infections,
such as excavated forms of Pneumocystis jiroveci pneu-
monia and mycobacterial infections.
More recently an antibody against langerin (CD207),
a Langerhans’ cell-specific lectin that initiates Birbeck
granule formation, has been tested to detect LCs in BALFigure 3 Computed tomography scan of the chest in a patient
with pulmonary Langerhans’ cell histiocytosis. The image shows
a combination of nodular and cystic changes.
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idiopathic pulmonary fibrosis.12 The percentage of langerin-
positive cells was almost identical to the percentage of
CD1a-positive cells in patients with PLCH, and was signifi-
cantly increased in this group in comparison with other
diseases. This new LC marker may thus be useful for
immunocytochemical analysis of BAL fluid in PLCH.
Transbronchial lung biopsy
TBB has shown poor sensitivity for the diagnosis of PLCH,
ranging from 10 to 40%.3,13 This low diagnostic yield is
mainly accounted for by the patchy nature of the disease,
with a focal distribution of the lesions, as well as the low
number of active nodules in advanced disease and the small
amounts of tissue obtained. Although immunohistochemical
techniques using monoclonal antibodies against CD1a and
S100 protein may be helpful, they do not significantly
increase the diagnostic relevance of TBB because of the
limitations of staining small biopsy samples (Fig. 4).13
Furthermore, the method is frequently complicated by
pneumothorax, meaning surgical lung biopsy is the safer
procedure for obtaining a histological confirmation.
However, the possibility of using TBB should be discussed on
a case-by-case basis with an experienced pulmonologist.
Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare disease that
predominantly affects young women in their reproductive
years. It occurs sporadically and in about 30% of women
with tuberous sclerosis complex (TSC), an autosomal
dominant syndrome characterized by hamartoma forma-
tion, seizures and cognitive defects.
LAM is characterized by the proliferation of LAM cells,
which leads to progressive cystic lung involvement, lymphatic
abnormalities and abdominal tumours (e.g. angiomyolipo-
mas).1,14 The lung lesions in LAM are characterized by nodules
or small clusters of LAM cells near cystic lesions and along
pulmonary bronchioles, blood vessels and lymphatics. LAMFigure 4 Detail of transbronchial lung biopsy from a patient
with pulmonary Langerhans’ cell histiocytosis. Langerhans’
cells show intense positivity for CD1a antigen (haematoxyline
eosin  400).cells exist in two subpopulations: myofibroblast-like spindle-
shaped cells, which express smooth muscle-specific proteins
such as a-actin, desmin and vimentin, and epithelioid-like
cells expressing glycoprotein gp100, a marker of melanoma
cells and immature melanocytes that react with the antibody
human melanoma black 45 (HMB45).14e16
Pneumothorax, progressive dyspnoea and chylous pleural
effusions are the main clinical manifestations of LAM; other
respiratory symptoms are cough, chyloptysis and
haemoptysis.17e21 Pneumothorax is often the first manifes-
tation, and recurrences are common.20 The characteristic
radiological feature is cysts. On HRCT they are usually round
with thin, regular walls, ranging from barely perceptible to
severalmillimetres in diameter. They are typically distributed
diffusely throughout the lungs, without sparing of the lung
bases (Fig. 5).22 A suggestive HRCT pattern in a patient with
angiomyolipoma, tuberous sclerosis complex or chylous
effusion (thoracic or abdominal) makes the diagnosis almost
certain. In other cases a morphological confirmation of the
diagnosis is necessary.
Bronchoalveolar lavage
In a comprehensive evaluation of 35 patients with LAM the
results of BAL showed a higher percentage of pigment-
laden macrophages than in normal subjects,19 most likely
resulting from microscopic pulmonary haemorrhages. NoFigure 5 Computed tomography scans in lymphangioleio-
myomatosis. (A) Numerous round, thin-walled cysts are distrib-
uted diffusely throughout the lungs, (B) without sparing of lung
bases.
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and BAL does not have diagnostic relevance in LAM.
Transbronchial lung biopsy
The gold standard for the diagnosis of LAM is a tissue biopsy of
lung or involved lymphatics showing nodular infiltration by
LAM cells. LAM has been included on the list of interstitial lung
diseases occasionally diagnosed by TBB.23 The use of TBB
findings for the diagnosis of LAM has been supported by
immunohistochemical techniques. In three TBB specimens
from patients with LAM (subsequently confirmed on open lung
biopsies) Bonetti and colleagues found similar artefactual
alveolar collapse (atelectasis). All specimens showed smooth
muscle-like cells with presence of actin and epithelioid
HMB45-positive cells, whereas none of 69 lesions used as
controls or 20 normal lung specimens showed HMB45-positive
cells.
Immunohistochemical studies of ten lung biopsy speci-
mens from patients with LAM (seven open lung biopsies, two
thoracoscopic biopsies, one TBB), using HMB45 and anti-
a smooth muscle actin antibody, found LAM cells that were
positive for HMB45 in all biopsy specimens, the percentage
of HMB45-positive cells ranging from 17 to 67%.24
In our experience, among seven TBBs performed in
patients with a clinicaleradiological suspicion of LAM, six
were diagnostic. In the remaining case the diagnosis of LAM
was confirmed by surgical lung biopsy (unpublished data).
No major complications were observed after any TBB
procedure. TBB may be a relative safe procedure and of
greater usefulness in LAM than PLCH, the more uniform
distribution of histological lesions in LAM possibly
accounting for this difference.
Recently, strong immunoreactivity for cathepsin K (a
papain-like cysteine protease with high matrix-degrading
activity) has been demonstrated restricted to LAM cells in
lung biopsy specimens and angiomyolipomas.25 This obser-
vation may provide a useful new marker for diagnosis, even
in difficult cases such as TBBs providing small samples.
Conclusion
In the appropriate clinical context the presence of typical
findings on an HRCT scan are often sufficient to establish
the diagnosis of PLCH. A suggestive HRCT pattern in asso-
ciation with supportive features (i.e. angiomyolipoma,
lymphangioleiomyoma, chylous collection) makes the
diagnosis of LAM very likely. When pathological confirma-
tion of the diagnosis is necessary, biopsy by video-assisted
thoracoscopic surgery or an open lung approach has the
best diagnostic yield in both diseases. Nevertheless, in the
appropriate clinical setting, the diagnosis may be rendered
based on the results of less invasive procedures.
Although BAL rarely establishes a definite diagnosis of
PLCH it still represents a useful step in the diagnostic
approach, to PLCH, mostly because of its safety and spec-
ificity, which in some cases can obviate the need for more
invasive procedures. The routine use of TBB in PLCH is not
recommended because of poor sensitivity and relatively
high risk, although it is of greater use in the diagnosis of
LAM.Conflict of interest statement
None.
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